Figure 5. Validation of TEP1 as a bona fide target of hsa-miR-660-3p. (A, B) After transfection with mimic hsa-miR-660-3p (A) and inhibitor (B), the RNA levels of TEP1 were detected by real-time PCR. (C, D) After transfection with mimic hsa-miR-660-3p (C) and inhibitor (D), the expression of TEP1 was detected by western blotting. (E) The sequences between TEP1 3’UTR and hsa-miR-660-3p were compared, and the complementary bases of red color indicate the seed sequence of hsa-miR-660-3p. The mutant TEP1 3’UTR was designed without the seed sequence. (F) The HSCs stably expressing the luciferase construct containing the wild-type (WT) or mutant (MT) TEP1 3’UTR were respectively transfected with hsa-miR-660-3p mimic, inhibitor and the negative control, and then the luciferase activity were examined.